Skip to main content

Table 4 Diagnosis-specific adjusted means of total costs over 12 months after baseline, insurer and secondary societal perspectives

From: Effectiveness and cost-effectiveness of treatment with additional enrollment to a homeopathic integrated care contract in Germany

  HOM group CON group  
Diagnosis N Cost utilization Adj. mean (€) (95% CI) N Cost utilization Adj. mean (€) (95% CI) Group Δ* p-value†
Insurer perspective (primary cost outcome)
 Migraine/headache 422 1654.42 (1309.80–1999.04) 265 1231.30 (839.57–1623.02) 423.13 < 0.001
 Allergic rhinitis 316 1137.50 (880.82–1394.17) 187 1038.28 (748.78–1327.79) 99.22 0.220
 Asthma 123 1463.28 (938.27–1988.29) 80 722.83 (116.94–1328.73) 740.45 < 0.001
 Atopic dermatitis 229 1269.32 (962.23–1576.40) 104 1129.83 (763.50–1496.17) 139.49 0.250
 Depression 452 1974.63 (1703.83–2245.43) 341 1553.96 (1241.84–1866.08) 420.67 < 0.001
Societal perspective
 Migraine/headache 422 4938.64 (2358.01–7519.28) 265 5010.48 (2077.35–7943.61) −71,84 0.924
 Allergic rhinitis 316 3073.44 (1125.04–5021.84) 187 3274.15 (1074.55–5473.74) −200,71 0.744
 Asthma 123 3022.62 (−43.81–6089.04) 80 1285.69 (−2244.58–4815.95) 1736,93 0.157
 Atopic dermatitis 229 7353.94 (5070.56–9637.31) 104 7536.04 (4812.85–10,259.24) −182,1 0.839
 Depression 452 9402.39 (6182.19–12,622.59) 341 7207.43 (3499.95–10,914.90) 2194,96 0.078
  1. * HOM group minus CON group, † adjusted for age, sex, education, residential state, complementary medicine affiliation, per protocol initial anamnesis, baseline utility value, total costs 12 months prior to baseline